当前位置:首页>产品中心>单抗/多抗>Anti-Cetuximab Polyclonal Antibody|抗西妥昔单抗多克隆抗体(靶标:西妥昔单抗(抗EGFR单抗))

Anti-Cetuximab Polyclonal Antibody|抗西妥昔单抗多克隆抗体(靶标:西妥昔单抗(抗EGFR单抗))

  • 货号:RB9TAF004014
  • 价格:面议
  • 点击:168

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA
特异性The product is specific for Cetuximab. This antibody serves as an excellent positive control for Cetuximab immunogenicity (ADA) assays.
靶标Rabbit polyclonal to Erbitux.
免疫原Cetuximab
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
稳定性和储存The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号CAS: 205923-56-4
背景信息Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab, as an epidermal growth factor receptor (EGFR) inhibitor, binds to EGFR.
• Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies., PMID:36408164
• Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy., PMID:21255939
备注For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 400
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 514
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 347
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 476
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 352
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 436
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 212
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 274
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 227
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 429
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 530
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 346
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 344
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 525
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 564
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 376
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 224
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 543
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 431
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 232
总计 33037 个记录,共 1652 页,当前第 1650 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00